Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
JOP : Journal of the Pancreas|September 12, 2012
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinomaParvin F Peddi, Sam Lubner, Robert McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumorsA Craig Lockhart, Martin Howard, Kenneth R Hande, et al.
Investigational New Drugs|August 14, 2014
Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumorsA Craig Lockhart, Shankar Sundaram, John Sarantopoulos, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|July 9, 2003
A clinical model of dermal wound angiogenesisA Craig Lockhart, Rod D Braun, Daohai Yu, et al.
Oncotarget|July 10, 2015
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsDavid S Hong, Peter Rosen, A Craig Lockhart, et al.
Investigational New Drugs|May 22, 2018
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumorsA Craig Lockhart, Todd M Bauer, Charu Aggarwal, et al.
Plos One|September 19, 2014
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancersLaura W Goff, Nilay Thakkar, Liping Du, et al.
Cancer Chemotherapy and Pharmacology|January 7, 2017
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation studyJohn Sarantopoulos, Alain C Mita, Aiwu He, et al.
Cancer Chemotherapy and Pharmacology|September 30, 2016
Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumorsJohn Sarantopoulos, Sanjay Goel, Vincent Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitorA Craig Lockhart, Rod D Braun, Daohai Yu, et al.
Pageof 10